Because of the emergence of quinolone-resistant N. gonorrhoeae in the United States, the current recommended gonorrhea treatment options are from a single class of antimicrobials—cephalosporins. Ceftriaxone, available only as an injection (125 mg intramuscularly), is the recommended regimen for uncomplicated urogenital and anorectal infection. Several other parenteral cephalosporins (ceftizoxime, cefoxitin, cefotaxime) are efficacious in treating gonorrhea but do not offer any substantial advantages over ceftriaxone. Cefixime, 400 mg, is the only oral regimen recommended for gonorrhea treatment. Single-dose oral regimens have potential benefits of convenience and reduced risk for needlestick injury in health care workers. However, as a result of the decision by the manufacturer to discontinue U.S. production, cefixime tablets have not been available in the United States since October 2002 (26). In 2004, Lupin (Mumbai, India) received approval from the U.S. Food and Drug Administration (FDA) to manufacture generic cefixime, currently available as a suspension (200 mg/5 mL), with approval of a tablet formulation anticipated in 2008. Several oral regimens for uncomplicated urogenital and anorectal gonococcal infections may be considered as alternative gonococcal therapies using the less stringent efficacy criterion (that is, lower bound of 95% CI ≥90%). Some evidence suggests that cefpodoxime, 400 mg, may be effective for treating urogenital and anorectal gonorrhea ((22), (27)). Cefuroxime axetil, 1 g, also meets the less stringent efficacy criteria, but it has poor pharmacodynamic characteristics that may select for stepwise increases in resistance, as has occurred with penicillin (28).